Dashboard
Manage Tickers

ALNY


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

intellia-freezes-key-trial-after-serious-liver-event-stock-tumbles
Intellia Freezes Key Trial After Serious L...
10/27/2025 14:38:29

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related advers...

peering-into-alnylam-pharmaceuticals-incs-recent-short-interest
Peering Into Alnylam Pharmaceuticals Inc's...
10/21/2025 14:00:42

truist-securities-maintains-buy-on-alnylam-pharmaceuticals-raises-price-target-to-535
Truist Securities Maintains Buy on Alnylam...
10/17/2025 13:46:03

Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price tar...

1000-invested-in-alnylam-pharmaceuticals-10-years-ago-would-be-worth-this-much-today
$1000 Invested In Alnylam Pharmaceuticals ...
10/14/2025 16:30:44

jp-morgan-maintains-overweight-on-alnylam-pharmaceuticals-lowers-price-target-to-473
JP Morgan Maintains Overweight on Alnylam ...
10/13/2025 13:53:37

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target ...

hc-wainwright--co-reiterates-buy-on-alnylam-pharmaceuticals-maintains-570-price-target
HC Wainwright & Co. Reiterates Buy on Alny...
10/10/2025 11:00:54

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintain...

27-analysts-assess-alnylam-pharmaceuticals-what-you-need-to-know
27 Analysts Assess Alnylam Pharmaceuticals...
10/06/2025 22:01:29

morgan-stanley-maintains-equal-weight-on-alnylam-pharmaceuticals-raises-price-target-to-475
Morgan Stanley Maintains Equal-Weight on A...
10/06/2025 13:47:47

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price ...

stifel-maintains-buy-on-alnylam-pharmaceuticals-raises-price-target-to-495
Stifel Maintains Buy on Alnylam Pharmaceut...
10/06/2025 12:28:51

Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $441...

alnylam-pulls-tv-ad-after-trump-crackdown-on-drug-industry-spots--bloomberg
'Alnylam Pulls TV Ad After Trump Crackdown...
10/02/2025 14:48:37

https://www.bloomberg.com/news/articles/2025-10-02/alnylam-pulls-tv-ad-after-trump-crackdown-on-drug-industry-spots?embedded-ch...

alnylam-begins-global-phase-3-trial-testing-new-hypertension-drug-zilebesiran-doses-first-patient-in-study-of-rnai-therapy-for-high-blood-pressure
Alnylam Begins Global Phase 3 Trial Testin...
10/01/2025 11:36:22

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the first patient has ...

reported-sunday-alnylam-pharmaceuticals-helios-b-phase-3-data-show-vutrisiran-cuts-gastrointestinal-events-by-up-to-49-in-attr-cm-patients
Reported Sunday, Alnylam Pharmaceuticals H...
09/29/2025 06:48:44

− Treatment with Vutrisiran Led to 37- 49% Lower Rates of Gastrointestinal Events, a Multisystem Manifestation of ATTR-CM, Acro...

alnylam-pharmaceuticals-announced-earlier-sunday-new-data-from-helios-b-phase-3-study-demonstrate-lower-rates-of-gastrointestinal-events-in-attr-cm-patients-treated-with-vutrisiran
Alnylam Pharmaceuticals Announced Earlier ...
09/28/2025 23:36:36

Alnylam Pharmaceuticals  today announced results from new analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an ...

1000-invested-in-alnylam-pharmaceuticals-5-years-ago-would-be-worth-this-much-today
$1000 Invested In Alnylam Pharmaceuticals ...
09/26/2025 21:58:22

Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 5 years by 10.45% on an annualized basis produ...

intellia-highlights-clinical-improvements-with-one-time-dose-of-experimental-drug
Intellia Highlights Clinical Improvements ...
09/25/2025 17:57:31

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of inv...

beyond-the-numbers-28-analysts-discuss-alnylam-pharmaceuticals-stock
Beyond The Numbers: 28 Analysts Discuss Al...
09/19/2025 14:01:37

rbc-capital-maintains-outperform-on-alnylam-pharmaceuticals-raises-price-target-to-500
RBC Capital Maintains Outperform on Alnyla...
09/19/2025 13:02:31

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target ...

Core News & Articles
Alnylam Joins Illumina And NashBio's Allia...
09/18/2025 13:22:18

Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene sile...

b-of-a-securities-maintains-buy-on-alnylam-pharmaceuticals-raises-price-target-to-520
B of A Securities Maintains Buy on Alnylam...
09/17/2025 13:19:42

B of A Securities analyst Tazeen Ahmad maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price targe...

goldman-sachs-maintains-buy-on-alnylam-pharmaceuticals-raises-price-target-to-566
Goldman Sachs Maintains Buy on Alnylam Pha...
09/16/2025 16:38:58

Goldman Sachs analyst Salveen Richter maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION